Featured Research

from universities, journals, and other organizations

Researchers Identify A Gene Essential For The Natural Killer Cell Response Against Cancer

Date:
October 21, 2002
Source:
Memorial Sloan-Kettering Cancer Center
Summary:
Scientists at Memorial Sloan-Kettering Cancer Center have identified a gene called MEF that is essential to the development of Natural Killer cells and Natural Killer T-cells, which play a vital role in the innate immune system. Their findings are published as the cover study in the October 2002 issue of Immunity from Cell Press.

NEW YORK, October 16, 2002 - Two parts of the body's immune system are critical for its normal functioning. One of these, the innate immune component, must defend the body against onslaughts from foreign substances it has never before seen. Failure of the immune system can result in cancer, autoimmune disease, or life threatening viral infections.

Scientists at Memorial Sloan-Kettering Cancer Center have identified a gene called MEF that is essential to the development of Natural Killer cells and Natural Killer T-cells, which play a vital role in the innate immune system. Their findings are published as the cover study in the October 2002 issue of Immunity from Cell Press. "By understanding how the MEF protein promotes the development and function of natural killer cells, we will develop ways to help the innate immune system better recognize and kill cancer cells," said Stephen D. Nimer, M.D., head of the Division of Hematology Oncology and the study's senior author. "We are planning future studies to learn how this can improve bone marrow transplant strategies."

"The differential regulation of perforin gene expression in the innate versus the adaptive immune system provides a selective target for future therapeutic interventions," explained H. Daniel Lacorazza, Ph.D., the study's first author.

###

Note: This study entitled, "The ETS Protein MEF Plays a Critical Role in Perforin Gene Expressio and the Development of Natural Killer and NK-T Cells", is available on line at http://www.Immunity.com.


Story Source:

The above story is based on materials provided by Memorial Sloan-Kettering Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Memorial Sloan-Kettering Cancer Center. "Researchers Identify A Gene Essential For The Natural Killer Cell Response Against Cancer." ScienceDaily. ScienceDaily, 21 October 2002. <www.sciencedaily.com/releases/2002/10/021021052417.htm>.
Memorial Sloan-Kettering Cancer Center. (2002, October 21). Researchers Identify A Gene Essential For The Natural Killer Cell Response Against Cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2002/10/021021052417.htm
Memorial Sloan-Kettering Cancer Center. "Researchers Identify A Gene Essential For The Natural Killer Cell Response Against Cancer." ScienceDaily. www.sciencedaily.com/releases/2002/10/021021052417.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins